Abstract 829P
Background
Follicular lymphoma (FL) is the second most common B-cell non-Hodgkin lymphoma that is defined by unique somatic mutation and gene expression profile. Differences in the genomic profile of FL by age and by sex have not been well characterized.
Methods
We analyzed data from 155 patients with FL who underwent next generation sequencing and RNA expression analysis using the Genomic Testing Cooperative Hematology Plus platform. The DNA and RNA panels assessed 179 genes and 1408 genes, respectively. Our analysis was based on sex (male n=75, female n=80) and age (<50 years, n=20; 50-74 years, n=109; >75 years, n=26). Data and statistics were analyzed with Bioconductor R package Maftools and Broad Institute Gene Set Enrichment Analysis.
Results
At least one somatic mutation in epigenetic genes: KMT2D (n=106), CREBBP (n=98), EZH2 (n=41) and EP300 (n=27) were present in 95% of all patients (n=155). Mutations in B2M were significantly enriched in females (10% vs 1.3%, p=0.035), while mutations in MEF2B were significantly enriched in males (24% vs 10%, p=0.030). Mutations in EP300 were enriched in the young cohort (<50; 35% vs 14%, p=0.047). Mutations in genes: BCR (Breakpoint Chain Region; 23% vs 3.9%, p=0.0033), CREBBP (81% vs 60%, p=0.047), STAT6 (23% vs 8.5%, p=0.042) and TET2 (19% vs 6.2%, p=0.045) were enriched in the elderly cohort (>75). All BCR mutations (missense and truncations), occurred within the N-terminus kinase domain of the gene. These mutations have not been well characterized in FL and are predicted to be deleterious; involving a coiled-coil domain essential for oligomerization and gene function. These mutations may compromise its function as a regulator of RAC1 and RHOA proteins. Correlation with limited available clinical data also suggests that these mutations are seen with aggressive FL or FL undergoing transformation. RNA expression did not show any significant differences based on age or sex.
Conclusions
Our study suggests that there are age and gender specific genomic alterations in FL. We plan to follow up with validation studies in a larger cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Genomic Testing Cooperative.
Funding
Has not received any funding.
Disclosure
A. Novak: Other, Personal, Funding, Research funding: Bristol Myers Squibb. M. Albitar: Financial Interests, Personal, Leadership Role, CEO, CMO and own stocks: Genomic Testing cooperative. H. Tun: Financial Interests, Personal and Institutional, Research Grant: Gossamar Bio, Acrotech; Financial Interests, Personal, Advisory Board: Curis. All other authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18